Lumos Pharma to Participate in Upcoming Investor Conferences
10 nov. 2021 17h06 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company...
Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates
03 nov. 2021 16h01 HE
|
Lumos Pharma, Inc.
Majority of OraGrowtH210 Trial sites are open with recent and imminent openings representing historically high enrollment sitesSix-month primary outcome data readout from OraGrowtH210 expected 2H 2023...
Lumos Pharma to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021
21 oct. 2021 16h05 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will...
Lumos Pharma to Participate in September Investor Conferences
02 sept. 2021 08h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company...
Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
05 août 2021 08h00 HE
|
Lumos Pharma, Inc.
• Lumos Pharma strengthens leadership team with promotion of John McKew, PhD to President, and addition of David B. Karpf, MD as Chief Medical Officer and Mark Bach, MD, PhD to Advisory Board •...
Lumos Pharma Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer
03 août 2021 08h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced that...
Lumos Pharma Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President
02 août 2021 08h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced that current...
Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark Bach, M.D., Ph.D., to Clinical Scientific Advisory Board
26 juil. 2021 16h18 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, July 26, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that Mark Bach,...
Lumos Pharma to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021
22 juil. 2021 08h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, July 22, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will...
Lumos Pharma Announces Clinical Updates
20 juil. 2021 16h01 HE
|
Lumos Pharma, Inc.
OraGrowtH210 Trial in PGHD primary outcome 6-month data now anticipated in 2H2023; treatment period to be extended to 12 monthsOraGrowtH212 PK/PD Trial initiated in Q2 2021; treatment period to be...